Journal of Clinical Oncology

Company

Related News

FDA Reviews Updated Taletrectinib Data in Advanced ROS1-Positive NSCLC

May 11, 2026

The FDA has accepted for review a supplemental application for taletrectinib in advanced ROS1-positive NSCLC, with a PDUFA date of January 4, 2027. Updated TRUST-I and TRUST-2 data showed high response rates, durable responses and no new safety signals.

Immunotherapy Timing and Radiation Strategies Show Mixed Results in Lung Cancer Trials

Mar 12, 2026

Recent studies reveal immunotherapy failed to improve survival in small-cell lung cancer when combined with chemoradiation, while timing of immunotherapy after radiation therapy affects outcomes in non-small cell lung cancer patients.